Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

2020481 citationsJournal Articlebronze Open Access

Authors

Bairavi Shankar · Sidney Kimmel Comprehensive Cancer Center

Jiajia Zhang · Bloomberg (United States)

Abdul Rafeh Naqash · East Carolina University

Patrick M. Forde · Johns Hopkins University

Josephine Feliciano · Johns Hopkins University

Kristen A. Marrone · Sidney Kimmel Comprehensive Cancer Center

David S. Ettinger

Abstract

In this multicenter cohort study, development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 6, Issue 12, pp. 1952-1952

DOI: 10.1001/jamaoncol.2020.5012

Field-Weighted Citation Impact: 21.28

Command Palette